Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.33, $1.21 worse than the analyst estimate of $1.54. Revenue for the quarter came in at $397.5 million versus the consensus estimate of $398.93 million.

GUIDANCE:

Emergent BioSolutions sees Q3 2021 revenue of $1700-1900 billion, versus the consensus of $1.8 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.